Literature DB >> 10815730

Redefining MDR-TB transmission 'hot spots'.

M C Becerra1, J Bayona, J Freeman, P E Farmer, J Y Kim.   

Abstract

Halting further spread of multidrug-resistant tuberculosis (MDR-TB) requires both new resources and a renewed discussion of priority setting informed by estimates of the existing burden of this disease. The 1997 report of the first phase of the global survey by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD) uses the indicator of the proportion of TB cases that are MDR-TB to identify MDR-TB 'hot spots'. We sought to refine the definition of MDR-TB transmission 'hot spots'. For this purpose, we obtained estimates of two additional indicators for regions where data are available: MDR-TB incidence per 100,000 population per year, and expected numbers of new patients with MDR-TB per year. There is generally much agreement in the three indicators considered, and some differences also appear. We conclude that it is useful, when defining indicators of MDR-TB transmission 'hot spots', to include estimates of underlying TB incidence rates and of absolute numbers of MDR-TB cases. Estimating the force of morbidity of MDR-TB in a population is important for comparing this burden across settings with very different underlying TB incidence rates; estimating the absolute number of MDR-TB patients will be critical for planning the delivery of directly observed MDR-TB therapy and the rational procurement of second-line drugs. Through this exercise, we aim to initiate discussion about improved methods of quantifying and comparing current MDR-TB transmission 'hot spots' that require intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815730

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China.

Authors:  Jun Yue; Wei Shi; Jingping Xie; Yao Li; Erliang Zeng; Honghai Wang
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  Comparison of flow cytometric and Alamar Blue tests with the proportional method for testing susceptibility of Mycobacterium tuberculosis to rifampin and isoniazid.

Authors:  Roberto S Reis; Ivan Neves; Sergio L S Lourenço; Leila S Fonseca; Maria Cristina S Lourenço
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

3.  Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China.

Authors:  Min Zhang; Jun Yue; Yan-Ping Yang; Hong-Mei Zhang; Jian-Qiang Lei; Rui-Liang Jin; Xue-Lian Zhang; Hong-Hai Wang
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Evaluation of Etest for susceptibility testing of Mycobacterium tuberculosis.

Authors:  M L Joloba; S Bajaksouzian; M R Jacobs
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

5.  Antimicrobial use and antimicrobial resistance: a population perspective.

Authors:  Marc Lipsitch; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

6.  A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis.

Authors:  Anuradha Kumar; Ana Guardia; Gonzalo Colmenarejo; Esther Pérez; Ruben R Gonzalez; Pedro Torres; David Calvo; Ruben M Gómez; Fátima Ortega; Elena Jiménez; Raquel C Gabarro; Joaquín Rullás; Lluis Ballell; David R Sherman
Journal:  ACS Infect Dis       Date:  2015-08-12       Impact factor: 5.084

7.  What is a Hotspot Anyway?

Authors:  Justin Lessler; Andrew S Azman; Heather S McKay; Sean M Moore
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

8.  Mycobacterium tuberculosis Complex Genotype Diversity and Drug Resistance Profiles in a Pediatric Population in Mexico.

Authors:  Mercedes Macías Parra; Jesús Kumate Rodríguez; José Luís Arredondo García; Yolanda López-Vidal; Mauricio Castañón-Arreola; Susana Balandrano; Nalin Rastogi; Pedro Gutiérrez Castrellón
Journal:  Tuberc Res Treat       Date:  2011-08-23

9.  Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study.

Authors:  Ted Cohen; Caroline Colijn; Bryson Finklea; Abigail Wright; Matteo Zignol; Alexander Pym; Megan Murray
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.